Slide 1: Exchange filing cover letter: Investor Presentation
15th May, 2020 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip
Slide 2: Investor Presentation Q4FY20
Investor Presentation Q4FY20 15-05-2020
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward- looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors tha
Slide 4: Navigating the Pandemic: Continuing focus on our strategic priorities while combatting Covid-19
Navigating the Pandemic: Continuing focus on our strategic priorities while combatting Covid-19 Our key priorities as we continue to deliver on our promise of ‘Caring for life’ Safety of our employees, patients and Ensuring continuity of our business to serve 1 communities we serve 2 patient needs C
Slide 5: In FY20, we made significant progress across our key priorities
In FY20, we made significant progress across our key priorities ▪ India Rx delivers 3rd consecutive quarter of market beating double digit growth; full India 1 Drive market beating year growth at 9% ▪ Trade generics continues to drive growth with 15%1 in Q4; second growth quarter in a growth row pos
Slide 6: Update on our strategic priorities: Harvesting growth opportunities across our businesses
Update on our strategic priorities: Harvesting growth opportunities across our businesses 1 ‘One-India’ South Africa and Emerging Markets 2 Private market execution in SA; consolidated Bringing together the might of 3 businesses presence in EMs • Portfolio Synergies: Successful transitions of select
Slide 7: Unlocking of Respiratory franchise in the US
Unlocking of Respiratory franchise in the US : Approval for generic Albuterol, successful completion of generic Advair® trials and filing of another complex respiratory asset Formulation / Pre-clinical Phase 1 Phase 2 Phase 3 Filed Approved Status Brand name Albuterol MDI / Approved Proventil (SABA)
Slide 8: Key highlights: Sustained growth momentum across businesses
Key highlights: Sustained growth momentum across businesses Overall Revenues EBITDA Margin 1 Strong Financial Performance 5% 7% ~19% ~15% Impacted by ~200bps due to Covid related (Q4 YoY Growth (FY20 YoY Growth) Excluding Cinacalcet in base) (FY20) (Q4FY20) cut-off India Rx India Gx South Africa Con
Slide 9: Expanding RoIC profile; continued focus on maintaining balance sheet health
Expanding RoIC1 profile; continued focus on maintaining balance sheet health with strong cash flow generation Net Debt Net Debt / Equity RoIC (Pre Tax) +300bps 0.10 12.5% 1,581 11.2% 9.4% 807 0.05 Mar'19 Mar'20 Mar'19 Mar'20 FY18 FY19 FY20 ▪ Repaid loan of USD 275 Mn in FY20 ahead of schedule; Paid
Slide 10: Financial Performance – Q4FY20
Financial Performance – Q4FY20 Revenues INR 4,376 Cr 7%1 EBITDA INR 652 Cr │~15% Q4 FY20 (Consolidated)2 Revenue2 Break-up Actuals Global API, Others, vs Q4 FY 19 (Rs Cr) 6% 2% Total Revenue from Europe, 5% 4,376 - 1% Operations a) Domestic Sales 1,739 13% Emerging India, 40% Mkts, 9% b) Int’l Sales
Slide 11: Financial Performance – FY20
Financial Performance – FY20 Revenues INR 17,132 Cr 5% EBITDA INR 3,230 Cr │~19% FY20 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs FY 19 (Rs Cr) 4% 2% Total Revenue from Europe, 5% 17,132 5% Operations Emerging a) Domestic Sales 6,819 7% India, 39% Mkts, 9% b) Int’l Sales 9,876 3%
Slide 12: India (Rx + Gx + CHL): Rx continues the momentum with market beating double digit growth
India (Rx + Gx+ CHL1) : Rx continues the momentum with market beating double digit growth; Gx fully recovered post model change YoY Q2 Q3 Q4 Rx delivers 3rd consecutive quarter of market beating double digit growth Cipla 13% 14% 12% Rx 9% FY YoY IPM2 13% 10% 10% Gx revives strongly since Q2 highligh
Slide 13: India (Rx + Gx + CHL): Focused execution driving growth across all 3 India businesses
India (Rx + Gx+ CHL1) : Focused execution driving growth across all 3 India businesses Q4Y-o-Y FY Y-o-Y Rs Cr Rs Cr 1,730 6,741 12% 6,420 5% 1,542 Q4 FY 19 Q4 FY 20 FY19 FY20 Key Business Highlights2 Market Market Cipla ▪ The Rx business grew 12% over 4QFY19 and 9% over FY19 driven by Therapy Rank S
Slide 14: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q4 Y-o-Y FY Y-o-Y $ Mn $ Mn South Africa Market SA Private Market 148 10% Q4 YoY 44 40 124 11% FY YoY ZAR Terms ZAR Terms 106 102 19 22 South Africa Private South Africa 54 52 204 210 Tender Others (SSA & CGA) Q4 FY19 Q4 FY20 FY19 FY20
Slide 15: North America: FY20 growth driven by optimization of IP led opportunity
North America: FY20 growth driven by optimization of IP led opportunity; building the foundation for Respiratory franchise in FY21 Launch of generic Achieved first-pass Unlocking of Albuterol; Only success in the Filing of another Respiratory approved generic phase 3 trials for complex inhaler franc
Slide 16: ANDA Portfolio & Pipeline (As on 31st March 2020)
ANDA1 Portfolio & Pipeline (As on 31st March 2020) Total 175 22 62 259 ANDAs 200 ANDA Portfolio 180 160 29 140 120 56 100 80 9 60 4 22 40 81 3 3 20 1 33 11 0 7 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd PEFPAR 2 Invagen Partnered ANDAs 1 Does not include Vet product AND
Slide 17: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn FY Growth: -17% FY Growth: +14% FY Growth: +5% 58 -1% 33 34 57 -5% 32 38% 25 Q4 FY19 Q4 FY20 Q4 FY19 Q4 FY20 Q4 FY19 Q4 FY20 ▪ Q4 revenues impacted significantly by month end logistics issues; to be ▪ Strong performance in key DTM1 ▪ Cont
Slide 18: Priorities for the FY21: Sustaining growth through the pandemic
Priorities for the FY21: Sustaining growth through the pandemic Managing Supply chain, optimizing costs and conserving cash o Business continuity planning for manufacturing, supply chain, R&D and marketing with focus on cost 1 optimization and cash management o Proactively de-risking the business wi
Slide 19: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q4FY20 18